Randomized phase III trial of S-1 plus cisplatin versus docetaxel plus cisplatin for advanced non-small-cell lung cancer (TCOG0701).
Nobuyuki Katakami(Takarazuka City Hospital), Hirofumi Michimae(Kitasato University), Hiroshi Isobe, Hironobu Ohmatsu(National Cancer Center Hospital East), Yuichi Takiguchi(Sanno Medical Center), Kunihiko Kobayashi(Saitama International Medical Center), Yoichi Nakamura(Yokohama Municipal Minato Red Cross Hospital), Koichi Minato, Akira Inoue(Tohoku University Hospital), Hiroshi Sakai(Hiroshima University), Masahiro Takeuchi(The University of Tokyo), Makoto Nishio(Japanese Foundation For Cancer Research), Shunichi Sugawara(Sendai Kousei Hospital), Akira Yokoyama(Niigata Cancer Center Hospital), Kaoru Kubota(Nippon Medical School Hospital), Shoji Kudoh(Japan Anti Tuberculosis Association), Hiroaki Okamoto(Yokohama Municipal Citizen's Hospital), Hideo Kunitoh(Japanese Red Cross Medical Center), Akihiko Gemma(Nippon Medical School), Masaaki Fukuda(Nagasaki Medical Center)
Cited by 17
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k